KaloBios up big again; potential deal with Geron may be the driver

Sep. 04, 2015 12:39 PM ETHumanigen, Inc. (HGEN)GERN, HGENBy: Douglas W. House, SA News Editor137 Comments
  • Thinly traded nano cap KaloBios Pharmaceuticals (KBIO +43.9%) jumps again in early trading on robust volume. Shares have more than doubled over the past two trading sessions.
  • A possible driver of the bullish action may be Geron's (GERN -3.5%) interest in acquiring an early-stage oncology asset via licensing or outright purchase of a company. In the company's Q4 earnings call in March, CEO Chip Scarlett said the due diligence process to assess potential candidates was underway.
  • Kalabios' two lead product candidates are KB004, a monoclonal antibody currently in Stage 2 development for myelofibrosis or myelodysplastic syndrome and KB003, a monoclonal antibody in Phase 1 development for chronic myelomonocytic leukemia.

Recommended For You

Comments (137)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.